DENKHAUS DONALD A 4
4 · CATALYST PHARMACEUTICALS, INC. · Filed Feb 19, 2025
Insider Transaction Report
Form 4
DENKHAUS DONALD A
Director
Transactions
- Exercise/Conversion
Common Stock, par value $0.001 per share
2025-02-14+4,000→ 495,079 total - Exercise/Conversion
Restricted Stock Units
2025-02-14−4,000→ 158,274 total→ Common Stock (4,000 underlying)
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
- [F2]Derivative securities vested in equal tranches, 1/3rd on February 14, 2023, 1/3rd on February 14, 2024 and 1/3rd on February 14, 2025.
- [F3]Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The final tranche of shares was delivered on February 14, 2025.